Janus Global Life Sciences Fund Class D (JNGLX)

59.23
Net Asset Value
-1.64%
1 Day
+12.48%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.84%
Expense Ratio
Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets in securities of companies that the portfolio manager believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Performance

1 month+0.40% 3 years+36.77%
3 months+8.75% 5 years+27.64%
1 year+45.82% Since inception+13.18%
Data through --

Peer Comparisonvs. Health

 JNGLXCategory
Performance 5-yr return+27.64%+22.35%
Expense ratio0.84%1.44%
Risk 5 year sharpe ratio1.811.49
Net assets$4.3B$3.9B
Average market cap$16.9B$35.3B
Average P/E28.625.2
Portfolio turnover52%52%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyJanus
Fund manager & tenureAndrew Acker / 7 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock72.21%
International stock23.43%
Cash2.73%
Fixed income1.64%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 94.74%
Consumer service 3.23%
Consumer goods 0.79%
Business service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
JNJ Johnson & Johnson2.98%
BIIB Biogen2.72%
AMGN Amgen2.56%
-- 2.30%
CELG Celgene2.28%
AET Aetna2.14%
PCYC Pharmacyclics Inc2.14%
MNK Mallinckrodt Plc2.05%
-- 2.05%
HCA HCA Holdings Inc1.90%

To view my watchlist

Not a member yet?

Sign up now for a free account